APGE — Apogee Therapeutics Balance Sheet
0.000.00%
- $2.19bn
- $1.67bn
- 28
- 26
- 35
- 20
Annual balance sheet for Apogee Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash | |||
Cash and Equivalents | |||
Short Term Investments | |||
Cash and Short Term Investments | 152 | 395 | 521 |
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 152 | 398 | 530 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | — | 2.59 | 13.3 |
Long Term Investments | |||
Other Long Term Assets | |||
Total Assets | 152 | 401 | 754 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Current Liabilities | 9.98 | 20.6 | 28.6 |
Total Long Term Debt | |||
Total Debt | |||
Total Other Liabilities | |||
Total Liabilities | 9.98 | 21.5 | 37.2 |
Redeemable Preferred Stock | |||
Non Redeemable Preferred Stock | |||
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Other Equity | |||
Total Equity | 142 | 380 | 717 |
Total Liabilities & Shareholders' Equity | 152 | 401 | 754 |
Total Common Shares Outstanding |